公开(公告)号：US20220251067A1

公开(公告)日：2022-08-11

申请号：US17574820

申请日：2022-01-13

Applicant: Novartis AG

Inventor： Christopher FARADY ,  Nina GOMMERMANN ,  Philipp JANSER ,  Angela MACKAY ,  Henri MATTES ,  Nichola SMITH ,  Catherine Fooks SOLOVAY ,  Nikolaus Johannes STIEFL ,  Eric VANGREVELINGHE ,  Juraj VELCICKY ,  Anette von MATT

IPC: C07D401/12 ,  C07D237/14 ,  C07D237/20 ,  C07D403/12 ,  C07D413/12 ,  C07D451/04

Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

公开(公告)号：US20210308140A1

公开(公告)日：2021-10-07

申请号：US17259252

申请日：2019-07-23

Applicant: Novartis AG

Inventor： Christopher FARADY ,  Nina GOMMERMANN ,  Philipp JANSER ,  Angela MACKAY ,  Henri MATTES ,  Nikolaus Johannes STIEFL ,  Juraj VELCICKY

IPC: A61K31/53 ,  A61K45/06 ,  A61K31/616 ,  C07D495/14 ,  C07D513/14

Abstract: The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of disease and disorders mediated by NLRP3.

公开(公告)号：US20130296332A1

公开(公告)日：2013-11-07

申请号：US13932173

申请日：2013-07-01

Applicant: NOVARTIS AG

Inventor： Hans ALLGEIER ,  Yves AUBERSON ,  David CARCACHE ,  Philipp FLOERSHEIM ,  Christel GUIBOURDENCHE ,  Wolfgang FROESTL ,  Jörg KALLEN ,  Manuel KOLLER ,  Henri MATTES ,  Joachim NOZULAK ,  David ORAIN ,  Johanne RENAUD

IPC: C07D239/96 ,  C07C207/00 ,  C07C229/56 ,  C07D413/04 ,  C07D405/04 ,  C07D403/04 ,  C07C271/58

CPC classification number: C07D239/96 ,  C07C207/00 ,  C07C229/56 ,  C07C229/64 ,  C07C229/66 ,  C07C255/18 ,  C07C265/12 ,  C07C271/58 ,  C07D207/337 ,  C07D231/12 ,  C07D237/08 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D307/16 ,  C07D307/54 ,  C07D309/12 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04

Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

Abstract translation: 本发明涉及式（I）的1H-喹唑啉-2,4-二酮，其中R 1和R 2如说明书中所定义，其制备，作为药物的用途，以及含有它们的药物组合物。 此外，公开了用于制备式（I）化合物的中间体和包含式（I）化合物的组合。